Skip to main content


RANO 2.0: Update to the Response Assessment in Neuro-Oncology (RANO) Criteria for High-and Low-Grade Glioma in Adults

Wednesday, January 31, 2024
12:00 PM ET

Complimentary Registration!  

This activity is provided by the Society for Neuro-Oncology.

Target Audience
Neuro-oncologists, medical oncologists, neurosurgeons, radiation oncologists, radiologists, neuropathologists, physicians/scientists, clinical and laboratory trainees, and allied health professionals.

Statement of Need/Program Overview
The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. Informed by data that allowed evaluation of features of the different criteria, updates to the RANO criteria (RANO 2.0) have been proposed. RANO 2.0 recommends a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. This webinar will provide an overview the development of the RANO criteria, details of RANO 2.0, and discuss remaining issues and future directions.

Educational Objectives 
After participating in this CME activity, participants should be able to:
  • Identify the challenges of response assessment in glioma trials.
  • Discuss the details of RANO 2.0 (Response Assessment in Neuro-Oncology for high- grade and low-grade glioma).
  • Analyze RANO 2.0 criteria and what future trials need to improve for response assessment of gliomas.
Program Agenda
Click here to view the current program. 

Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation 
The Society for Neuro-Oncology designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit 
In order to receive credit for this activity, the participant must attend the meeting virtually and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant at the conclusion of the webinar from The Society for Neuro-Oncology with the subject line "Instructions to Receive Credit for RANO 2.0 webinar." 

For technical assistance with claiming CME credit, please email [email protected]  .

Deadline to claim CE Credit will be Thursday February 29, 2024, at 11:59 pm ET.
Disclosure of Relevant Financial Relationships
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view the disclosure list, click here. 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at [email protected]